发明名称 INHIBITORS OF POLO-LIKE KINASE
摘要 The present invention provides compounds having a structure according to Formula (I):;;or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
申请公布号 US2015126502(A1) 申请公布日期 2015.05.07
申请号 US201514596824 申请日期 2015.01.14
申请人 Elan Pharmaceuticals, Inc. 发明人 GALEMMO Robert A.;ARTIS Dean R.;YE Xiaocong Michael;Aubele Danielle;TRUONG Anh;BOWERS Simeon;Hom Roy K.;ZHU Yong-Liang;NEITZ R. Jeffrey;SEALY Jennifer;ADLER Marc;BEROZA Paul;ANDERSON John P.
分类号 C07D475/00;C07D498/14;C07D519/00;C07D487/14 主分类号 C07D475/00
代理机构 代理人
主权项 1. A compound having a structure according to Formula (I): or a salt or solvate thereof, wherein: X is C or N and the dashed line represents a single or double bond; A is a ring selected from the group consisting of phenyl, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, imidazole, thiazole, isothiazole, isoxazole, triazole, thiadiazole, benzimidazole, indole, pyrrolo[2,3-b]pyridine, quinoline, pyrrolidine, piperidine, piperazine, and dihydro-imidazole; R1 is methyl (e.g. —CD3 or —CH3, more preferably —CH3); R2 is hydrogen, methyl (e.g. —CD3 or —CH3), ethyl (e.g. —CD2CD3 or —CH2CH3), —CH2-cyclopropyl, or —CH2CF3; R3 is methyl (e.g. —CD3 or —CH3), ethyl (e.g. —CD2CD3 or —CH2CH3), —CH2-cyclopropyl, or —CH2CF3; or R2 and R3, together with the carbon atom to which they are attached, are optionally joined to form cyclobutyl; R4 is selected from the group consisting of —NH2, —NHCH3, —NHcyclopropyl, pyrrolidine, —CH2-cyclopropyl, —CH(CH3)-cyclopropyl, cyclopropyl, cyclobutyl optionally substituted with 1 or 2 fluoro, cyclopentyl optionally substituted with 1 or 2 fluoro, isopropyl (e.g. —CH(CH3)2 or —CD(CD3)2), —CH2CH2CF3, tetrahydropyran, tetrahydrofuran, oxetane, phenyl optionally substituted with 1 or 2 substituents R7, pyrazole optionally substituted with 1 substituent R8, and pyrimidine; or R4 and R3, together with the atoms to which they are attached, are optionally joined to form a substituted or unsubstituted 5- to 7-membered heterocyclic ring selected from the group consisting of whereinrepresents the core ring of Formula I, i.e. the N attached to R4 and the C attached to R3; or R4, R2 and R3, together with the atoms to which they are attached, are optionally joined to form a substituted or unsubstituted 7-membered heterocyclic ring selected from the group consisting of whereinrepresents the core ring of Formula I, i.e. the N attached to R4 and the C attached to R3/R2; R5 is hydrogen, —Br, —CN, —CH3, —CH2CN, —CH2CH2NH2, —OH, —O−, ═O, —OCH3, —Obenzyl, —C(O)OH, —C(O)OCH3, —C(O)OCH2CH3, —C(O)NH2, —C(O)NHCH3, —C(O)N(CH3)2,—NH2, ═NH, —NHCH3, —N(CH3)2, —NHS(O)2CH3, —S(O)2CH3, phenyl, thiazole, pyridine or pyrazine; R6 is hydrogen, —Cl, —Br, —CH3, —CF3, —CH2NH2, —NH2, —CH2NHC(O)OCH3, —CH2NHC(O)CH3, —CH2NHC(O)phenyl, —CH2NHS(O)2CH3, —CH2NHS(O)2phenyl, —NHC(O)CH3, —NHC(O)OCH3, —NHC(O)phenyl, —NHS(O)2CH3, —NHS(O)2phenyl, —CH≡CHphenyl, cyclopropyl, cyclopentenyl, benzyl, phenyl optionally sub with 1, 2 or 3 substituents R9, pyridine optionally substituted with 1 fluoro, pyrimidine, pyrazine, pyridazine, pyrazole, thiazole, oxazole, thiophene optionally substituted with 1 chloro, pyrrolidine, oxazolidinone, pyrrolidinone, dihydropyran, tetrahydropyran, morpholine, 4-methyl-piperazine, pyrrolidine-dione, pyridinone, isoquinoline, or quinoline; R7 at each occurrence is independently —C(O)NH2, fluoro, chloro, cyano, pyrazole, triazole, pyridine or pyrimidine; R8 is methyl or 2-(trimethylsilyl)ethoxy)methyl, cyclopropyl, or —CH2-cyclopropyl; and R9 at each occurrence is independently selected from the group consisting of fluoro, chloro, bromo, —S(O)2CH3, —OCF3, —CF3, —CN, pyridine, triazole, and pyrazole.
地址 South San Francisco CA US